Intravenous Nalbuphine Versus Lidocaine for Prevention of Propofol Injection Pain

NCT07422558 | Not Yet Recruiting

• 1 other identifier: ANA-PROP-01
• Study Type: interventional
• Target: 92
• Locations: 0 countries
• Sites: N/A

Brief Summary

Propofol is a commonly used intravenous anesthetic agent, but its administration is frequently associated with injection pain, causing patient discomfort and agitation. Various pharmacological agents have been used to reduce this pain, including nalbuphine and lidocaine; however, results from previous studies remain conflicting. This randomized clinical trial aims to compare the effectiveness of intravenous nalbuphine versus intravenous lidocaine in reducing the frequency of propofol-induced injection pain in patients undergoing elective general surgery procedures.

Conditions

Procedural Pain

Outcome Measures

Primary Outcomes (1)

• Frequency of propofol- induced injection pain

  Presence of injection pain assessed using a four-point pain scale during propofol injection until loss of eyelash reflex. Pain score ≥1 will be considered as presence of injection pain.

  During induction of anesthesia (within 1-2 minutes of propofol administration

Study Arms (2)

Nalbupine group

EXPERIMENTAL

Patient recieving intravenous nalbuphine prior to propofol induction

Drug: Nalbuphine

Lidocaine group

ACTIVE COMPARATOR

Patient recieving intravenous lidocaine prior to propofol induction

Drug: Lidocaine

Interventions

Nalbuphine DRUG

Intravenous nalbuphine 0.1mg/kg administred 60second prior to induction with propofol

Nalbupine group

Lidocaine DRUG

Intravenous lidocaine 4.5mg/kg (maximum 300mg) administred 60sec prior to induction with propofol

Lidocaine group

Eligibility Criteria

• Age: 18 Years - 60 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Age 18-60 years
• Either male or female
• ASA physical status I or II
• Scheduled for elective general surgery under general anesthesia using propofol

You may not qualify if:

• Known hypersensitivity to propofol, nalbuphine, or lidocaine
• Emergency surgery
• Use of analgesics prior to surgery
• Pregnant women
• Lactating women

Sponsors & Collaborators

• Hayatabad Medical Complex: lead

Related Links

• Related Info
• Related Info

MeSH Terms

Conditions

Pain, Procedural

Interventions

Nalbuphine; Lidocaine

Condition Hierarchy (Ancestors)

Pain; Neurologic Manifestations; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

Morphinans; Opiate Alkaloids; Alkaloids; Heterocyclic Compounds; Heterocyclic Compounds, Bridged-Ring; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Phenanthrenes; Polycyclic Aromatic Hydrocarbons; Polycyclic Compounds; Acetanilides; Anilides; Amides; Organic Chemicals; Aniline Compounds; Amines

Study Officials

• Dr.Arina kore Trainee medical officer, MBBS

  PGMI/Hayatabad Medical complex(HMC),Peshawar

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Dr.Arina kore Trainee medical officer, MBBS

CONTACT

+923446835431; Kore2k15@gmail.com

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER GOV
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Assistant professor

Study Record Dates

• First Submitted: February 13, 2026
• First Posted: February 20, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): August 1, 2026
• Study Completion (Estimated): August 1, 2026
• Last Updated: February 20, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share